10 · Policy & regulatory watch
Policy & regulatory watch
Bookmarks need a Mind Club sign-in. How sign-in works
An RNAi approval, no CMS prices yet with ten days to the deadline, and drugmakers’ pledges on trial sites in China.
| Agency | Action | Detail |
|---|---|---|
| FDA (11.18; announced 11.19) | Approval | Livsayis (cemdisiran), Regeneron, for adults with acetylcholine receptor antibody positive generalized myasthenia gravis, per Alnylam; FDA’s novel approvals list dates the action 11.18 |
| CMS | Negotiated prices for 2028 | Not yet published as of 11.20; the CMS page, last modified 11.02, still says negotiations are under way (call 10) |
| White House (11.18) | FDA commissioner | Withdrew Heidi Overton’s nomination, first reported 11.17; Kyle Diamantas remains acting commissioner, as reported |
| House Select Committee on China | Trial sites | Merck, Lilly, AbbVie, Pfizer and BMS said they will not open new trial sites in Xinjiang or at sites tied to China’s military, as reported; existing sites are not covered |
| FDA (11.19) | Filing | Humacyte submitted a supplemental BLA for its acellular tissue engineered vessel in dialysis access |
CMS negotiated prices page (opens another website in a new tab) Gov; Alnylam, via Yahoo Finance (11.19) (opens another website in a new tab); Humacyte, via BioSpace (11.19) (opens another website in a new tab) Co; FDA Novel Drug Approvals 2026 (opens another website in a new tab) Gov; Healio (11.18) (opens another website in a new tab); Fierce Healthcare (opens another website in a new tab); STAT (11.19) (opens another website in a new tab) Press. We found no CRL, advisory committee, clinical hold or guidance dated in the window.
RED TEAM
We rely on a company release for the Livsayis approval; FDA’s list confirms the 11.18 date; we did not read the label. The trial-site pledges cover new sites only, so how much changes in practice is unclear. Analysis